Interestingly, the similar mutation frequency was observed between tumors and tumor-matched mucosa, indicating that these FSMs driven by Msh2 deletion may not be sufficient to drive the tumor development and that secondary mutations may be required. This evidence concerns the gene MSH2 and neoplasm.